Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly


Enrollment is complete in the placebo-controlled Phase 3 PATHFNDR-1 study evaluating safety and efficacy of once-daily oral paltusotine in acromegaly patients

Crinetics Announces October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces October 2022 inducement grants: the stock options were granted as inducements material to 11 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism


The UK Medicines and Healthcare products Regulatory Agency has granted CRN04777 an “Innovation Passport” for the treatment of congenital hyperinsulinism.

Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer


Crinetics appoints Dana Pizzuti, M.D., a 30-year pharmaceutical industry veteran, to the newly created role of chief development officer

Crinetics Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces September 2022 inducement grants: the stock options were granted as inducements material to 13 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).